Carl P. Sherr & Co. LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Carl P. Sherr & Co. LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,526 shares of the company’s stock after buying an additional 24 shares during the quarter. Eli Lilly and Company makes up approximately 2.6% of Carl P. Sherr & Co. LLC’s portfolio, making the stock its 7th largest position. Carl P. Sherr & Co. LLC’s holdings in Eli Lilly and Company were worth $4,896,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. LRI Investments LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth $81,000. Objective Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth $239,000. Westwood Holdings Group Inc. grew its holdings in shares of Eli Lilly and Company by 5.4% during the 1st quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock worth $2,987,000 after purchasing an additional 196 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 13.6% in the first quarter. EverSource Wealth Advisors LLC now owns 3,509 shares of the company’s stock valued at $2,741,000 after buying an additional 420 shares in the last quarter. Finally, American Trust boosted its stake in Eli Lilly and Company by 0.6% in the first quarter. American Trust now owns 2,493 shares of the company’s stock valued at $1,939,000 after buying an additional 14 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $788.19 on Friday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a market capitalization of $748.24 billion, a price-to-earnings ratio of 85.21, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The business has a 50-day moving average of $854.42 and a 200-day moving average of $869.27.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 earnings per share. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.66%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LLY. Truist Financial raised their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Berenberg Bank raised their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.